Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Waldenström's macroglobulinemia.
K. Raman Desikan
, Madhav V. Dhodapkar
, Bart Barlogie
Research output
:
Contribution to journal
›
Review article
›
peer-review
7
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Waldenström's macroglobulinemia.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Waldenström Macroglobulinemia
100%
Purine Analogues
100%
Complete Remission
50%
β2-microglobulin (β2-MG)
50%
Clinical Syndromes
25%
Interferon-α (IFN-α)
25%
Comprehensive Approach
25%
Hemoglobin
25%
Initial Treatment
25%
Therapeutic Agents
25%
Working Diagnosis
25%
Prognostic Factors
25%
Induction Therapy
25%
Maintenance Therapy
25%
Alkylator
25%
Alkylating Agents
25%
Rituxan
25%
High-dose Therapy
25%
Peripheral Stem Cells
25%
Immunology and Microbiology
Macroglobulinemia
100%
Beta2-Microglobulin
100%
interferon
50%
Drug Megadose
50%
Stem Cell
50%
Low Drug Dose
50%
Rituximab
50%
Hemoglobin
50%
Pharmacology, Toxicology and Pharmaceutical Science
Purine
100%
Purine Derivative
100%
Waldenstroem macroglobulinemia
100%
Remission
50%
Beta 2 Microglobulin
50%
Interferon
25%
Syndrome
25%
Rituximab
25%
Alkylating Agent
25%
Medicine and Dentistry
Waldenström's Macroglobulinemia
100%
Purine
100%
Beta 2 Microglobulin
50%
Interferon
25%
Drug Megadose
25%
Low Drug Dose
25%
Maintenance Therapy
25%
Clinical Syndrome
25%
Rituximab
25%
Alkylating Antineoplastic Agent
25%
Stem Cell
25%